9 assets in Monocytic Leukemia

Therapeutic assets addressing Monocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Enasidenib Monocytic Leukemia	Tian Yi Zhang	P1/2	CCC (50)
Cyclophosphamide Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (46)
Daratumumab Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (46)
Fludarabine Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (46)
Lispro-Ph20 Component Rhuph20 Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (46)
Azacitidine Monocytic Leukemia	University of Colorado, Denver	P1	CC (43)
Mitoxantrone Monocytic Leukemia	University of Colorado, Denver	P1	CC (43)
Venetoclax Monocytic Leukemia	University of Colorado, Denver	P1	CC (43)
ft538 Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	D (29)